Cabozantinib significantly improves progression free survival compared to sunitinib as first-line treatment for advanced kidney cancer
Review by a blinded independent radiology review committee (IRC) has [...]
Tivozanib plus nivolumab combination enters phase II clinical trials
The phase I dose-escalation phase of the TiNivo trial, which [...]
Personalised therapy for papillary renal cell carcinoma (pRCC)
A recent paper published in European Urology has characterised the [...]
First ever World Kidney Cancer Q&A Day highlights global burden
The first ever World Kidney Cancer Q&A Day is marked [...]
World Kidney Cancer Day 22nd June 2017: Kidney cancer risk factors
This article discusses five potential risk factors for kidney cancer, [...]
Novel treatment options for kidney cancer presented at ASCO 2017
The following video is an interview between PracticeUpdate and Dr Bradley [...]
Dalantercept plus axitinib fails to improve progression-free survival in people with kidney cancer
The development of dalantercept, an anaplastic lymphoma kinase 1 (ALK1) [...]
Initiation of phase Ib clinical trial of cabozantinib plus atezolizumab for advanced/metastatic solid tumours
Exelixis announced today the start of a phase 1b clinical trial [...]
Nivolumab and cabozantinib accepted for use within NHS Scotland for advanced kidney cancer
The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, [...]
16-gene recurrence score for high-risk kidney cancer offers prognostic value
Results from a phase III trial presented at the American [...]
